According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The drug will be available in 600 hospitals and 105 DTPs
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Tislelizumab is now approved for seven indications in China
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
Subscribe To Our Newsletter & Stay Updated
